Abstract
Dr. Pascale Richetta is Executive Vice President and Head of the Bone Patient Value Unit at UCB (Brussels, Belgium). She joined UCB in 2016 following over 20 years’ experience in the pharma and biotech industry. After completing her MD at the University of Poitiers (France), she spent time as vice president at Abbvie/Abbott and has also held positions at GlaxoSmithKline, Ipsen and Servier. Through the course of her career she acquired impressive commercial experience managing both traditional pharmaceuticals and complex biologics and her knowledge of markets around the world is key to helping UCB prepare for future product launches.
Highlights
Could you tell us a little about your career to date? I started my professional career as a physician, but my first roles in pharma were in France at Servier and Ipsen Biotech
I joined UCB a year and a half ago as the head of the Bone Patient Value Unit, and my main aim is to take UCB’s investigational osteoporosis medicine, which is being co-developed with Amgen, through its development phases and upon regulatory approval ensure we are prepared for its worldwide launch
What does your position at UCB involve? My aim as head of the Bone Patient Value Unit (bPVU) is to support the larger mission of UCB; we are very much an innovation-driven global biopharmaceutical company focused on addressing unmet needs and creating value for patients by improving their lives and thereby creating value for society in general
Summary
Could you tell us a little about your career to date? I started my professional career as a physician, but my first roles in pharma were in France (where I grew up) at Servier and Ipsen Biotech. The other aspect that we are focused on is working to address the unmet medical need in post-fracture care. We are currently seeing a gap in the treatment and management of osteoporosis, especially in the post-fracture setting, with one out of five patients remaining undiagnosed and untreated [1].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
